Literature DB >> 3337904

Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.

J Whang-Peng1, R C Young, E C Lee, D L Longo, G P Schechter, V T DeVita.   

Abstract

Cytogenetic studies of 68 patients who developed secondary leukemia (SL)/dysmyelopoietic syndrome (DMS) after extensive chemotherapy and/or radiation therapy as well as patients who developed SL/DMS without such treatment showed that those patients who received radiation alone or with chemotherapy had more extensive numerical and structural abnormalities than those who received only chemotherapy. In terms of the specific chromosomal abnormalities, there are no differences between the various treatment groups. Hypodiploidy is the most common form of aneuploidy in these patients, with the most common numerical abnormality being the loss of chromosome 7. The most common structural abnormalities involved chromosomes 3 and 5. When compared with patients with de novo leukemia and DMS, the chromosomal abnormalities in these patients are more complex and extensive. Serial studies revealed that cytogenetic abnormalities do not precede the development of hematologic changes by significant time periods.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337904

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  M-FISH analysis shows that complex chromosome aberrations induced by alpha -particle tracks are cumulative products of localized rearrangements.

Authors:  Rhona M Anderson; David L Stevens; Dudley T Goodhead
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-30       Impact factor: 11.205

2.  Acute myelogenous leukemia in a rheumatoid arthritis patient under cyclosporine A therapy.

Authors:  P Casoli; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

3.  Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation.

Authors:  Hiroyuki Fujisaki; Kenji Takai; Sawada Akihisa; Sadao Tokimasa; Yoshiko Matsuda; Hideaki Ohta; Yuko Osugi; Ji Yoo Kim; Gaku Hosoi; Masahiro Sako; Junichi Hara
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Authors:  M M Hawkins; L M Wilson; M A Stovall; H B Marsden; M H Potok; J E Kingston; J M Chessells
Journal:  BMJ       Date:  1992-04-11

Review 5.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

6.  Multiple granulocytic sarcomas in essential thrombocythemia.

Authors:  Yasuhiro Tanaka; Yuya Nagai; Minako Mori; Haruyuki Fujita; Katsuhiro Togami; Masayuki Kurata; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Kyoko Tanaka; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

7.  Chronic myelogenous leukemia following radiation therapy for testicular seminoma.

Authors:  A Iurlo; P Foa; A T Maiolo; E E Polli
Journal:  Blut       Date:  1989-12

8.  The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

Authors:  Constantine S Tam; Lynne V Abruzzo; Katherine I Lin; Jorge Cortes; Alice Lynn; Michael J Keating; Deborah A Thomas; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

9.  Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy.

Authors:  A Hayani; D H Mahoney; L D Taylor
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

10.  Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.

Authors:  Yasuhiro Tanaka; Masayuki Kurata; Katsuhiro Togami; Haruyuki Fujita; Naoko Watanabe; Akiko Matsushita; Akinori Maeda; Kenichi Nagai; Akiko Sada; Toshimitsu Matsui; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.